The Immune System's Hidden Key, the STING Receptor – A New Immunotherapy Target

New-generation medicines continue to be developed for cancer treatment every day. In November 2018, Naturepublished a report involving 44 scientists announcing new-generation immunotherapy medicines for cancer treatment.
As is known, the immune system consists of complex cellular structures. It protects against infections and diseases. Immune cells can detect thousands of pathogens, from viruses to parasitic worms. They can also distinguish healthy cells from pathogens or damaged cells. This study identified new-generation medicines acting through a known central mediator of our innate immune system, the STING pathway , enabling the immune system to recognize and destroy cancer cells.
For this purpose, the focus was a protein called STING . When STING becomes active, it directs T cells to recognize and destroy cancer cells. So how can this protein be activated?
Targeting the STING Receptor to Activate T Cells
Research found that the STING receptor, located in the intracellular organelle called the endoplasmic reticulum, plays a role in the immune system distinguishing pathogen and normal DNA . In this study, researchers developed a STING-activating drug group called amidobenzimidazole , which they designed . These new-generation medicines have many advantages. Amidobenzimidazole medicines can be injected directly into the blood and effectively target hard-to-reach solid organ tumors. In mouse cancer models, these medicines also activated immune memory cells . In other words, if cancer recurs, immune cells were thought to be ready to attack cancer cells, potentially eliminating the need for additional treatment.

Figure Description: When intracellular STING receptors are stimulated, they increase production of immune-activating molecules such as type-1 interferon and cytokines, promoting activation of macrophages, dendritic and natural killer (NK) cells and enabling tumor-specific T-cell training and differentiation.
Natural STING pathway agonists (activators) are small molecules expressed by bacteria and immune cells. This study, however, found that synthetically produced amidobenzimidazole agents had much higher activity than natural STING molecules. These synthetic STING activators are being developed for both systemic administration (intravenously throughout the body) and direct tumor injection to stimulate an immune response to tumor antigens. This can also be thought of as a cancer vaccine .
It must be emphasized that molecules targeting STING have not yet been tested in patients or approved for clinical use by any authority. For potential cancer medicines activating STING, phase-1 clinical studies are planned to begin in 2019.
Sources
Design of amidobenzimidazole STING receptor agonists with systemic activity
Nature, 07 November 2018.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.